Crossmark

Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial

Crossref DOI link: https://doi.org/10.1186/s12885-019-5541-4

Published Online: 2019-06-14

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Brown, Sarah R.

Hall, Andrew

Buckley, Hannah L.

Flanagan, Louise

Gonzalez de Castro, David

Farnell, Kate

Moss, Laura

Gregory, Rebecca

Newbold, Kate

Du, Yong

Flux, Glenn

Wadsley, Jonathan
Funding

Funding for this research was provided by:

Cancer Research UK (A18349)
License Information

Text and Data Mining valid from 2019-06-14

Version of Record valid from 2019-06-14
More Information

Article History

Received: 21 March 2019

Accepted: 28 March 2019

First Online: 14 June 2019

Ethics approval and consent to participate

: The trial has received ethics approval from the NHS National Research Ethics Service (NRES) East Midlands-Leicester South (15/EM/0455). All participants provide full informed consent to participate in SEL-I-METRY.

: Not applicable.

: SRB, AH, HB, LF, KF, LM, RG, YD and GF declare that they have no competing interests. JW has previously received honoraria for attending Advisory Boards for both AstraZeneca and Sanofi-Genzyme and has received honoraria/support to attend educational meetings from Eisai, Bayer and Sobi. KN has received honoraria for teaching and consultancy from Eisai, AstraZeneca, Sanofi-Genzyme and Sobi. DGdC has received honoraria, consultancy and speaker fees as well as research funding from AstraZeneca.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below